NRIX - Company ID 0001549595
The table below shows Nurix Therapeutics, Inc.'s balance sheet line items across its last 6 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $246.96M | $110.00M | $54.63M | $64.47M | $80.51M | $119.36M |
| Short-term investments | - | - | - | $244.67M | $215.21M | $161.79M |
| Receivables | - | - | - | - | - | - |
| Inventory | - | - | - | - | - | - |
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| Total current assets |
| $606.82M |
| $619.39M |
| $295.50M |
| $318.45M |
| $311.12M |
| $298.43M |
| Property, plant & equipment | $22.49M | $17.76M | $16.81M | $17.16M | $11.34M | $6.67M |
| Goodwill | - | - | - | - | - | - |
| Total assets | $688.13M | $669.34M | $355.60M | $416.76M | $476.77M | $396.34M |
| Accounts payable | $11.21M | $11.48M | $6.40M | $5.06M | $6.65M | $3.41M |
| Total current liabilities | $86.47M | $95.85M | $86.96M | $70.66M | $66.26M | $44.54M |
| Long-term debt | - | - | - | - | - | - |
| Total liabilities | $149.39M | $142.35M | $155.10M | $113.06M | $134.47M | $106.07M |
| Retained earnings | -$1.00B | -$738.77M | -$545.20M | -$401.25M | -$220.89M | -$103.70M |
| Total equity | $538.75M | $526.99M | $200.49M | $303.70M | $342.30M | $290.27M |